CoDa Therapeutics announced that it has secured $19.2 million for a Phase II study of its topical gel Nexagon, which reduces protein production to encourage wound healing. In a previous midstage trial of the gel involving patients with venous leg ulcers, about 33% of participants' wounds were healed after four weeks.

Related Summaries